T ailoring insulin therapy to the blood glucose profiles of patients with diabetes is indisputably a rational strategy. Yet, with the advent of various insulin preparations, the pharmaceutical industry aggressively promotes products to fit the needs of most, if not all, patients with diabetes. Of note, the Diabetes Control and Complications Trial investigators used several different insulin regimens to achieve blood glucose control in patients with type 1 diabetes (1), a population generally more homogeneous in terms of underlying pathophysiologic characteristics than those with type 2 diabetes. Thus, the need for an individualized approach to insulin therapy in patients with diabetes cannot be overemphasized. Nevertheless, certain subgroups of patients with diabetes can be differentiated from each other according to the pattern of blood glucose changes during the day. Therefore, profiling these groups may help practitioners rationally choose a particular insulin regimen. The insulin regimen should subsequently be modified on the basis of the individual's response to therapy. We describe 3 common blood glucose profiles that represent typical patterns among patients with diabetes. On the basis of the blood glucose profile, we suggest an initial insulin regimen that would then be modified according to individual responsiveness. To prime the discussion, we briefly review the pharmacologic characteristics of currently available insulin products.
This review is based on previously published manuscripts that were identified through a MEDLINE search (1996 to 25 February 2006) of English-language literature. The literature search was limited to core clinical journals that have accessible full texts, and the key phrase used was therapeutic use of insulin. A total of 420 manuscripts were reviewed, but only a select number are quoted to avoid repetitiveness and to adhere to space limitations. Individual references were chosen at the discretion of the authors. All authors independently reviewed the relevant available literature. This literature, along with our clinical experiences, was used to construct practical suggestions. been used to target postprandial hyperglycemia, its timeaction profile is far from the physiologic pancreatic postprandial insulin burst. The advent of recombinant DNA technology has made it possible to improve the time-action profile of regular insulin. The structural modifications of these novel analogues are shown in Figure 1 . Currently, there are 3 rapid-acting insulin analogues with similar pharmacokinetic profiles that are more suitable for targeting postprandial hyperglycemia: insulin lispro (Humalog, Eli Lilly, Indianapolis, Indiana), insulin aspart (Novolog, Novo Nordisk, Bagsvaerd, Denmark), and insulin glulisine (Apidra, Aventis Pharmaceuticals, Inc., Bridgewater, New Jersey). These insulin analogues are rapidly absorbed (Ͻ 30 minutes) after subcutaneous injection, peak at 1 hour, and have a shorter duration of action (3 to 4 hours) than regular insulin (10 -12). Furthermore, the intraindividual variability in time to maximum serum insulin concentration is clinically significantly less for rapid-acting insulin analogues than for regular human insulin preparations (10 -13).
The rapid-acting insulin analogues should be injected 5 to 15 minutes before a meal. However, in infants or in older adults with dementia who both have unpredictable eating patterns, rapid-acting analogues can be administered after the meal without excessive deterioration of glycemic control (14, 15) .
Intermediate-acting insulins, such as neutral protamine Hagedorn (NPH) or lente insulin, have a delayed onset of action ranging between 2 to 4 hours, can take approximately 6 to 7 hours to reach peak concentration, and can last up to 20 hours. This leads to a distinct peakand-trough effect, and therefore, when used as basal insulin, 2 or more injections are often required each day to minimize the daily excursions of insulin levels. Recently, production of lente and ultralente insulins was discontinued because of their decreasing market shares.
Long-acting insulin glargine has an onset of action of approximately 2 hours, reaches a plateau of biological action at 4 to 6 hours, and lasts up to 24 hours (9, 16). The timing of insulin glargine administration should be individualized, although it is minimally important as long as the insulin is administered at the same time every day (17) .
Compared with bedtime NPH insulin, insulin glargine is associated with less nocturnal hypoglycemia in patients with type 2 diabetes (28.8% vs. 12.6%, respectively; P ϭ 0.011) (18, 19) . If nocturnal hypoglycemia occurs after evening or bedtime administration of insulin glargine, the timing of the injection should be changed to the morning.
Insulin detemir is another long-acting basal insulin analogue that is soluble at neutral pH. It has a unique mechanism of action (20 -23) . After subcutaneous injection, in- (24) . Of note, there is clinically significant interindividual variability in the pharmacokinetics of insulin, and the profile often depends on the dose that is administered. However, the pharmacokinetics of insulin analogues have less intraindividual variability than human insulin.
The availability of insulin analogues enhances flexibility and convenience for insulin-treated patients, and this increased flexibility in insulin timing is associated with an improvement in quality-of-life measures (25) . The increasing variety of insulin preparations allows more opportunities to achieve control. The downside is the increased challenge facing health care providers in making the right choices in insulin therapy.
CHOOSING THE INSULIN PREPARATION
Protocols for insulin use depend on patient location, comorbid conditions, and available resources. All patients with type 1 diabetes require insulin therapy, whereas the indications for insulin therapy in patients with type 2 dia- • ϭ Insulin lispro differs from human insulin by the substitution of proline with lysine at position 28 and the substitution of lysine with proline at position 29 of the insulin ␤ chain.
‡ ϭ Insulin aspart is designed with the single replacement of the amino acid proline by aspartic acid at position 28 of the human insulin ␤ chain. * ϭ Insulin glulisine is designed with the substitution of the amino acid lysine with asparagine at position 3 of the human insulin ␤ chain and by substitution of the amino acid lysine at position 29 with glutamine. † ϭ Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and 2 arginines are added to the C-terminus of the ␤ chain. ࡗ ϭ Insulin detemir is designed to bind albumin in plasma after absorption. Threonine is omitted from position 30 of the insulin ␤ chain and replaced by myristic acid, a C14 fatty acid chain. betes include symptomatic hyperglycemia, failure of oral therapy, pregnancy, acute illness necessitating surgery, acute myocardial infarction or cardiovascular surgery, and admission to an intensive care unit. The proper timing of initiation of insulin therapy, when oral agents are not achieving glycemic goals, depends on such variables as severity of hyperglycemia, economic and psychosocial circumstances of the patient, and his or her preferences. In general, insulin is the most cost-effective intervention in patients who have not obtained their glycemic goal despite taking 2 or more oral agents. Patients with diabetes present with a wide spectrum of blood glucose profiles ( Table 2 ).
Profile 1: Fasting and Daytime Postprandial
Hyperglycemia ("Round-the-Clock" Hyperglycemia)
Profile 1 is common in diabetic patients referred to endocrinology practices. These patients have either type 1 diabetes or type 2 diabetes with significant insulinopenia.
The pathophysiologic characteristics of fasting and postprandial hyperglycemia are complex. The fasting blood glucose level is determined predominantly by the regulation of glucose production by the liver (26 -28) . The level of insulin in the portal circulation suppresses glycogenolysis and gluconeogenesis. Peripheral insulin decreases glucagon secretion and limits lipolysis with subsequent free fatty acid-induced gluconeogenesis (29, 30) .
Many factors affect postprandial hyperglycemia (31, 32) , including the amount of carbohydrate ingestion and rate of absorption (33) , the loss of early-phase insulin secretion (34), the rate of glucagon secretion (33) , the effect of these hormones on glucose uptake in muscle, and suppression of hepatic glucose production (35) .
Patients with Type 1 Diabetes
For patients in intensive care units, the most appropriate management would be the initiation of an intravenous insulin drip with frequent monitoring and titration of the insulin dose (36, 37) . Many insulin infusion protocols are currently used. The protocol for the insulin drip we have been using is shown in Figure 2 . The intravenous insulin drip should use human regular insulin only because there is no advantage of any currently available insulin analogues in this setting.
Patients with new-onset type 1 diabetes are best treated with a combination of background basal insulin and short-acting insulin taken before meals. The background insulin is preferably initiated as insulin glargine, although NPH insulin or insulin detemir given twice per day are alternative approaches. The rapid-acting insulin analogues are preferred for prandial coverage. Subsequent adjustments in insulin protocol or the decision to initiate insulin pump therapy will depend on individual responses and preferences. Many patients with type 1 diabetes may benefit from continuous subcutaneous insulin infusion therapy delivered by commercially available insulin pumps. This approach provides increased flexibility in dosing and may improve quality of life in some patients. A meta-analysis of the studies evaluating the efficacy and safety of insulin pump therapy has found a modest advantage of this approach compared with multiple-dose insulin injection protocols (38, 39) . Currently, initiation of insulin pump therapy should be individualized, considering the patient's preferences, lifestyle, and self-care capabilities. The discussion of the choice of devices used and the implementation protocols of therapy are beyond the scope of this paper.
Patients with Type 2 Diabetes
Patients with type 2 diabetes and round-the-clock hyperglycemia have significant insulinopenia with or without severe insulin resistance. Examples of such patients include those with latent adult-onset type 1 diabetes, those who are obese and have severe insulin resistance, those who are older and frail (often women with brittle diabetes) (40) , and those receiving high doses of glucocorticoid therapy Adapted from the protocol that is used at the Saint Louis University Hospital with some modifications. Glucose is obtained with fingerstick unless otherwise specified. The protocol is based on expert opinion and has not yet been validated prospectively.
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In patients with type 2 diabetes, intermediate-or longacting insulin may be added to existing oral antiglycemic agents to control fasting blood glucose levels. Adjustment of the insulin dose is first based on the fasting blood glucose level. For example, the initial dose of insulin glargine would depend on the patient's weight. In general, a starting dose of 10 to 15 U given at bedtime is appropriate. The dose is subsequently increased by 1 to 2 U for every 1.1 mmol/L (20 mg/dL) of fasting blood glucose over 5.5 mmol/L (100 mg/dL) (19) ( Table 3 ). The dose should not be adjusted more frequently than 3-day intervals. Preprandial supplemental rapid-acting insulin is often needed. However, many patients with type 2 diabetes require only 1 daily injection of insulin glargine without the addition of preprandial insulin. Of note, although insulin glargine can last up to 24 hours, a waning effect can be seen as early as 15 hours (9), and some patients require 2 doses of insulin glargine in a 24-hour period. However, there is no evidence that this regimen has any advantage over conventional NPH insulin. The preprandial insulin dose should be prescribed according to individual sensitivities and the amount of carbohydrates that are ingested. In general, a dose of 5 to 10 U of short-or rapid-acting insulin is initially prescribed and further adjustments are made to the preprandial insulin dose on the basis of the individual's response.
Another approach is to calculate the initial preprandial insulin dose according to an estimate of the patient's insulin requirements. The total insulin requirement for a patient with type 2 diabetes is estimated to be 0.6 U/kg (36, 37) . Approximately half of the total dose will be basal longacting or intermediate-acting insulin, and one sixth of the total dose (0.1 U/kg per meal) will be rapid-acting insulin administered before meals. To improve flexibility, the patient may learn how to adjust for changes in daily intake of dietary carbohydrates. An "insulin-to-carbohydrate" ratio may be calculated to estimate the amount of insulin necessary to cover ingested carbohydrates. This is accomplished by dividing the total preprandial daily insulin dose (in units) by the dietary carbohydrate intake (in grams). Thus, if the patient modifies the composition of carbohydrates at any specific meal, he or she can readjust the preprandial insulin dose to accommodate the carbohydrate load. A supplemental insulin dose ("correction factor") may be added to correct for ambient blood glucose levels before meals. This supplemental dose is calculated by dividing 1500 if regular human insulin is used or 1800 (or 1700, according to some published literature) (42, 43) if rapid-acting insulin analogue is used by the total insulin requirement. This provides an estimate of the patient's sensitivity to insulin (that is, the expected decrease in blood glucose level [in mg/dL] in response to 1 U of insulin). The correction dose of supplemental insulin may be added to the meal-determined insulin requirements to calculate the total preprandial insulin dose that is needed. These preliminary estimates are then adjusted on the basis of the individual's response to therapy. However, these calculations are subject to large interindividual variability, and as such, they should be regarded as first approximations.
Premixed insulins may also be used to achieve control. These preparations are more convenient and less prone to errors in dosing but limit flexibility in diet and lifestyle. The premixed insulin analogues can be preferable to premixed human insulin preparations because they can be taken within 15 minutes of a meal and have better postprandial coverage (44) .
Currently, there is no strong rationale to favor glargine, NPH insulin, insulin detemir, or fixed-ratio insulin as the preferred agent for initiating insulin therapy. In 1 study, adding once-daily glargine to sulfonylurea and metformin treatment was more effective than withdrawing oral antiglycemic drugs and initiating twice-daily injections of human premixed 70/30 insulin (45) . In this trial, glargine was adjusted according to fasting blood glucose levels by * The efficacy and safety of the insulin regimen selected has been shown in clinical trials (that is, evidence-based recommendation). † Expert opinion. If the patient has an elevated blood glucose level at lunchtime, the breakfast rapid-acting insulin dose should be adjusted; if the patient has an elevated preprandial blood glucose level at dinner time, the lunchtime rapid-acting insulin dose should be adjusted; if the patient has an elevated bedtime glucose level, the dinnertime rapid-acting insulin dose should be adjusted. Adapted from references 19, 36, 37, and 41. ‡ Reduction in insulin dose of 4 or more units as appropriate.
using the algorithm summarized in Table 3 . The design of this study, notably the withdrawal of oral antiglycemic drugs in the insulin 70/30 arm of the study, does not allow for direct comparison between the insulin glargine regimen and the twice-daily premixed human insulin regimen. In another study of 233 insulin-naive diabetic patients receiving metformin alone or in combination with other oral antiglycemic agents, initiating insulin therapy with twicedaily biphasic insulin aspart 70/30 was more effective in achieving hemoglobin A 1c targets than once-daily glargine (41) . In this study, insulin therapy was initiated at a total daily dose of 10 to 12 U administered within 15 minutes before breakfast and supper (evening meal). The presupper dose was titrated on the basis of fasting blood glucose levels and the prebreakfast dose was titrated on the basis of presupper levels to achieve a target blood glucose value of 4.4 to 6.05 mmol/L (80 to 110 mg/dL). Dose titration was based on plasma glucose levels from the preceding 3 days ( Table 4) . If 2 of the 3 readings for a specified period (prebreakfast or presupper) were not within target, the insulin dose was adjusted on the basis of the lower of the 2 plasma glucose readings unless hypoglycemia was occurring (41) . In a similar study, insulin therapy was initiated with either twice-daily insulin lispro mix 75/25 or once-daily glargine, both taken concomitantly with metformin (46) . Reduction in hemoglobin A 1c level was greater in the lispro mix group, and more patients reached the target hemoglobin A 1c level of less than 7% in 16 weeks when treated with the lispro mix than with glargine (41% vs. 22%; P Ͻ 0.001) (46) . Currently, the decision of whether to start the patient on glargine administered once per day, intermediate-acting insulin administered twice per day, or mixed-insulin preparation must be individualized.
Profile 2: Fasting Hyperglycemia and Daytime Euglycemia
Patients who have this blood glucose profile tend to be middle-aged, overweight, or possibly active individuals who often consume most of their daily calories from supper through snacks until bedtime ( Table 2) . Alternatively, some individuals may eat many small meals during the day (a "grazing" pattern of eating) and be physically active. If the individual is already taking oral antidiabetic agents, the clinical efficacy of the oral agent, especially of the insulin secretagogues, may not last for 24 hours. The insulin of choice in these patients is either an intermediate-acting insulin preparation, such as NPH or insulin detemir given at bedtime, or short-acting insulin given before supper. The choice of insulin is determined by the level of blood glucose at bedtime. If the bedtime blood glucose level exceeds 7.7 mmol/L (140 mg/dL), then the patient can reduce postdinner snacking (a preferred option, especially if the goal is modest weight loss) or take short-acting insulin before supper. Some patients may benefit from mixing regular human insulin with rapid-acting insulin. That combination may be taken within 15 minutes of supper and provides enough insulin to cover postdinner snacking. If the individual's bedtime blood glucose level is not elevated, then intermediate-acting insulin at bedtime would be preferred. In these persons, checking midnight blood glucose levels periodically (that is, once per week initially) would ensure that the individual is not experiencing nighttime hypoglycemia that may be aggravating the elevations in fasting blood glucose levels.
Profile 3: Daytime Hyperglycemia and Fasting Euglycemia
This profile with predominantly postprandial hyperglycemia can occur in patients with early-stage type 2 diabetes or in those with advanced disease who are already taking more than 1 oral antiglycemic drug. It is also a common profile in many women with gestational diabetes. In addition, several other patient groups have this blood glucose profile ( Table 2) , including patients with end-stage liver disease or end-stage kidney disease and those receiving high-dose glucocorticoid therapy once daily in the morning for immunosuppression or for treatment of chronic obstructive pulmonary disease.
If these patients are willing to limit the amount of carbohydrates consumed per meal and maintain consistency from day to day, they may do well on a single injection of intermediate-acting insulin administered in the morning. However, many patients, especially those receiv- ing glucocorticoid therapy, require 1 or more preprandial injections of short-acting insulin to control blood glucose levels. Rapid-acting analogues are not approved for use during pregnancy, although retrospective reviews of medical records of diabetic women treated with insulin lispro (Humalog, Eli Lilly) before conception and throughout pregnancy did not find any adverse maternal or fetal outcomes (47) . In a small study comparing the efficacy of insulin aspart with that of regular human insulin in women with gestational diabetes, insulin aspart was associated with effective postprandial glycemic control (48) . The safety and efficacy of insulin analogues during pregnancy were recently reviewed (49) . There are no randomized studies showing the safety and efficacy of insulin analogues during pregnancy.
As inhaled insulin becomes available, persons who predominantly have postprandial hyperglycemia and do not have any clinically significant comorbid conditions may benefit from the convenience of this mode of therapy.
COMBINATION THERAPY FOR INSULIN AND ORAL AGENTS
Insulin therapy is often combined with oral agents in patients with type 2 diabetes or in those who have type 1 diabetes and insulin resistance (3, 28, 35, 50) (that is, those requiring Ͼ40 U of insulin per day). In patients with early secondary failure of sulfonylurea agents, the addition of bedtime insulin may be sufficient to achieve the glycemic goal. This regimen of bedtime insulin and daytime sulfonylurea has been successfully implemented in many patients with type 2 diabetes (3). The concomitant use of metformin or a thiazolidenedione agent in patients with insulin resistance may be beneficial. The advantage of metformin is that it limits the weight gain commonly observed with initiation of insulin therapy. The continuation of metformin or thiazolidenedione therapy in insulin-treated patients may allow simplification of insulin administration schedules (3, 28, 35, 50) . The addition of an ␣-glucosidase inhibitor, such as acarbose or miglitol, with 1 or more meals per day may also allow reduction of the number of daily insulin injections (28) . For a more comprehensive review of available oral antidiabetic agents, the reader is referred to previously published reviews on the topic (3, 28, 35, 50) .
MONITORING GLYCEMIC CONTROL
Recommendations for monitoring glycemic control in insulin-treated patients include daily self-monitoring of blood glucose levels and periodic measurement of glycated hemoglobin. Self-monitoring of blood glucose levels provides a profile of daily glycemic fluctuation, reflecting effects of meals, physical activity, and action of the specific components of the insulin regimen. The glycated hemoglobin assesses the long-term adequacy of the treatment plan in meeting glycemic goals (51) .
At the initiation of insulin therapy, patients are generally asked to monitor blood glucose levels 4 times daily, including before meals and at bedtime. Once satisfactory glycemic control has been established, patients using intensive multiple-injection regimens or insulin pumps must continue to monitor blood glucose levels at least 3 times daily. Patients treated with simpler regimens, such as 1 or 2 daily injections of intermediate-or long-acting insulin, may need to test only once or twice per day (51) . In the latter case, rotating premeal and bedtime self-monitoring blood glucose tests over a period of several weeks should provide sufficient data at each essential test point to produce an adequate overall profile of glycemic control. The self-monitoring schedules should be adjusted to specific patient needs and may require intensification during intercurrent illness, during pregnancy, or when there are changes in daily routines. Additional tests may be necessary, for example, at 2:00 a.m. or 1 to 2 hours after a meal to assess overnight hypoglycemia and postprandial glycemic excursions, respectively. Although the importance of postprandial self-monitoring of blood glucose has been shown for pregnant women, the routine use of this measurement is controversial in insulin-treated patients who are not pregnant (32, 52, 53) .
The glycated hemoglobin (also known as glycohemoglobin, glycosylated hemoglobin, hemoglobin A 1c ) reflects nonenzymatic glucose binding to hemoglobin in circulating erythrocytes. Because erythrocyte turnover is 90 to 120 days, the glycated hemoglobin measurement represents the mean glycemic control over the preceding 2 to 3 months. Conditions that alter erythrocyte turnover, such as severe anemia, hemolysis, or hemoglobinopathy, will result in glycated hemoglobin measurements that do not correlate with the results of self-monitoring tests (54). Lack of correlation should trigger investigation for such underlying conditions and for inaccurate measurement or reporting of self-monitored blood glucose. Based on results of the Diabetes Complications and Control Trial, the goal for nonpregnant, insulin-treated adults is a glycated hemoglobin level of 7.0% or less that is as close to the normal range as possible without subjecting the patient to repetitive severe hypoglycemia (54). Glycated hemoglobin is measured every 3 months after initiation or alteration of treatment for diabetes until targeted goals have been achieved. Once glycemic control is stabilized in the desired range, measurements may be limited to 6-month intervals (51) .
CONCLUSIONS
The spectrum of individual blood glucose profiles is wide. For practical purposes, and at the risk of oversimplification, these blood glucose profiles can be divided into 3 general patterns ( Table 2) . Prescribing insulin is a dynamic process, and the patient should be prepared to adjust the regimen as additional information about blood glucose changes becomes available. Diabetes educators and nutritionists play a vital role in the management of these patients. In addition to proficiency in counting carbohydrates and diligence in self-monitoring of blood glucose, patients with diabetes should be able to continuously evaluate their individual blood glucose responses to foods they consume and to physical activity. In general, insulin analogues enhance flexibility and convenience for insulin-treated patients, and recent studies have shown that flexible intensive insulin management can be cost-effective and can be associated with an improvement in quality of life (13) . It is now easier to achieve the American Diabetes Association's recommended goal of a hemoglobin A 1c level of less than 7%. However, the new insulin preparations are more expensive than conventional insulin preparations and the cost may be a limiting factor for some patients.
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